Nebacumab

Nebacumab is a human monoclonal antibody developed for the treatment of sepsis.[1] It has been withdrawn in 1993 because it failed to reduce mortality in clinical trials.[2]

Nebacumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	endotoxin
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	J06BC01 (WHO)
Identifiers
CAS Number	138661-01-5^N
ChemSpider	none
UNII	908FWN27WK
KEGG	D05126^Y
^NY (what is this?) (verify)

References

Derkx B, Wittes J, McCloskey R (April 1999). "Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group". Clinical Infectious Diseases. 28 (4): 770–7. doi:10.1086/515184. PMID 10825037.
WHO: Consolidated List of Products

Monoclonal antibodies for infectious disease and toxins

Human	Efungumab^†

Human	Ansuvimab Atoltivimab (+maftivimab/odesivimab) Bamlanivimab^† Casirivimab^† (+imdevimab)^† Diridavumab^§ Exbivirumab^§ Foravirumab^§ Imdevimab^† Libivirumab^§ Maftivimab Odesivimab Rafivirumab^§ Regavirumab^§ Sevirumab^† Suptavumab Tuvirumab^§
Chimeric	Cosfroviximab Larcaviximab Porgaviximab
Humanized	Felvizumab^§ Lenvervimab^† Motavizumab^† Palivizumab Suvizumab^§

Human	Nebacumab Panobacumab^§ Raxibacumab
Mouse	Edobacomab^§
Chimeric	Pagibaximab^†
Humanized	Tefibazumab^†

Human	Actoxumab^§ Bezlotoxumab Suvratoxumab
Chimeric	Obiltoxaximab
Humanized	Urtoxazumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Immune sera and immunoglobulins (J06)

Polyclonal antibodies

IVIG	Anthrax immune globulin Rho(D) immune globulin Hepatitis B immune globulin Zoster-immune globulin
Antiserum	Antivenom

Monoclonal antibodies

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.